Recursion Pharmaceuticals, Inc. (RXRX) Q2 2025 Earnings Call Transcript

Recursion Pharmaceuticals (RXRX) highlighted significant progress in its Q2 2025 earnings call, emphasizing the evolution and deployment of its AI-driven Recursion OS 2.0 platform. Key advancements include the open-sourced Boltz-2 for efficient protein binding predictions and the ClinTech platform, which is accelerating clinical trial design and patient enrollment projections by up to 50%. The company detailed pipeline progress across internal programs like CDK7 and RBM39, with multiple data readouts expected by early 2026, and noted continued milestone achievements in partnerships with Sanofi and Roche. Financially, RXRX reported a strong cash position of $533 million, projecting a cash runway through Q4 2027, supported by expense management and over $100 million in anticipated partnership inflows by end-2026.

Analysis

Recursion Pharmaceuticals' Q2 2025 report underscores a period of significant operational integration and technological advancement following its merger with Exscientia. The core of the company's narrative is the deployment of Recursion OS 2.0, an AI-driven platform now being applied end-to-end from target discovery to clinical trial simulation. A key technological highlight is Boltz-2, an open-sourced protein-ligand binding model developed with Nvidia and MIT that reportedly achieves predictive efficacy comparable to traditional methods but with 1,000-fold less compute. Management is also deploying its ClinTech platform across all programs, citing potential for 50% faster clinical trial enrollment and improved dose optimization for 30% more patients. This platform progress is being translated into a tangible pipeline with a dense catalyst calendar over the next 18 months, including key data readouts for its CDK7 and FAP programs in H2 2025, and initial data for its RBM39 program in H1 2026. Financially, the company appears robust, ending the quarter with $533 million in cash and guiding for a runway through Q4 2027. This position is supported by a commitment to reduce cash burn to below $390 million in 2026 and the pursuit of over $100 million in probability-weighted partnership milestones by the end of 2026, evidenced by a recent milestone achievement with Sanofi.

Key Decisions for Investors

• Investors should closely monitor the upcoming clinical data readouts in H2 2025 for the FAP and CDK7 programs, as these results represent critical validation points for the Recursion OS platform's ability to impact later-stage assets.
• The company's execution on its partnership-related guidance, specifically the goal of achieving over $100 million in milestones by the end of 2026, serves as a key measure of external validation and a vital source of non-dilutive funding.
• Given the stated cash runway through Q4 2027, attention should be paid to management's ability to maintain its projected burn rate, as this financial discipline provides a multi-year window to reach key clinical inflection points without near-term financing pressures.
• Consider the strategic decision to open-source technologies like Boltz-2 as a sign of the company's confidence in its proprietary, data-generating phenomics platform as its core competitive advantage, a thesis that requires long-term observation.